Alleviating Effect of Lafutidine on Toxicity of S-1: Adjuvant Chemotherapy of Gastric Cancer (AEOLUS)
- Conditions
- Gastric neoplasm
- Registration Number
- JPRN-UMIN000002703
- Lead Sponsor
- Pharma Valley Center , Shizuoka Industrial Foundation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 200
Not provided
1) Patient with active double cancer (synchronous double cancer and metachronous double cancer), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 2) Patient with administration contraindication of S-1 and Lafutidine 3) Patient with regular use of H2-blocker, PPI, furucytocin, fenytoin, or warfarin. 4) Patients with the past history of severe allergic reactions. 5) Patient with severe complications, such as paralytic ileus, bowel obstruction, interstitial pneumonitis, pulmonary fibrosis, or uncontrollable diabetes mellitus, arrhythmias, heart failure, liver cirrhosis, and active hepatitis) 6) Severe watery diarrhea. 7) pregnant or nursing patient or with intent to bear baby 8) Exclude the patients who are recognized as inadequate patients by doctors with responsibility in this trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Completion rate of S-1 treatment according to planned
- Secondary Outcome Measures
Name Time Method 1) Toxicity 2) The relative total administration dose of S-1